HempFusion Wellness set to become the exclusive CBD supplier for a Mount Sinai Hospital clinical trial

HempFusion Wellness Inc (TSE:CBD.U) (OTCMKTS:CBDHF) (FRA:8OO) announced that it has been selected by Mount Sinai Medical Hospital in New York City to be the exclusive brand and the sole CBD supplier in a six-month clinical trial. 

The company said the clinical trial, which is expected to begin in March, is comprised of two studies conducted by board-certified cardiologist and electrophysiologist Dr. David Harnick, and is one of the first of its kind in the area of CBD’s effect on targeted cardiology markers. 

“This is the second clinical trial HempFusion is proudly participating in,” HempFusion Wellness CEO Jason Mitchell said in a statement. 

READ: HempFusion utilizing the power of whole-food hemp nutrition

He added: “We are committed to furthering research in the area of hemp-derived CBD and this study at Mount Sinai Hospital in New York City is a significant expansion of our efforts that reinforces our continued focus on the safe and effective use of hemp-derived CBD products.”

Dr. Harnick also weighed in on the announcement, stating: “Studying the potential effects that CBD may have on cardiology markers may potentially unlock some of the scientific mysteries that exist today.”

He continued: “We know that there is evidence that CBD may have beneficial effects on the body, but the exact scope of those effects remains to be determined. There have been no published randomized prospective controlled trials evaluating the effects of CBD on these cardiac markers, so this research may prove to be groundbreaking.”

The company noted that Dr. Harnick has constructed this long-term clinical trial to collect data that will assist in a deeper understanding of CBD’s effect on the body, adding that he chose HempFusion for its rigors in regulatory standards, toxicology studies for safety and quality control adherence.

As well, HempFusion reported that its CBD products are also part of the ValidCare Human Observational liver and male reproductive toxicology studies, exploring the effect of CBD on liver enzymes.

The company said results from the study are expected in the coming weeks from the one year of planning and execution related to what many are considering to be the largest Human Observational liver and male reproductive toxicology studies done to date.

HempFusion added that the CBD used in these studies is the same hemp-derived CBD available to the public.

HempFusion Wellness is a health and wellness supplement company utilizing the power of whole-food hemp nutrition. It manufactures, markets, and sells hemp-based cannabidiol (CBD) and probiotic products in the US and Europe. 

Contact Sean at [email protected]

Story by ProactiveInvestors